

Supporting Information

Synthesis and oligomerization of cysteinyl nucleosides

Miklós Bege^{a,b,c}, Ilona Bereczki^a, Dénes J. Molnár^a, Máté Kicsák^a, Krisztina Pénzes-Daku^d, Zsuzsanna Bereczky^d, Györgyi Ferenc^e, Lajos Kovács^f, Pál Herczegh^a and Anikó Borbás^{a,*}

^a Department of Pharmaceutical Chemistry, University of Debrecen, Debrecen, H-4032, Hungary

^b Doctoral School of Pharmaceutical Sciences, University of Debrecen, Debrecen, H-4032, Hungary

^c MTA-DE Molecular Recognition and Interaction Research Group, University of Debrecen, Debrecen, H-4032, Hungary

^d Division of Clinical Laboratory Science, University of Debrecen, Debrecen, H-4032, Hungary

^e Nucleic Acid Synthesis Laboratory, Biological Research Center, Szeged, H-6726, Hungary

^f Nucleic Acids Laboratory, Department of Medicinal Chemistry, University of Szeged, H-6720 Szeged, Hungary

Table of contents

HPLC-MS characterisation of compound 13	S2
NMR spectra of the compounds	S4




Figure S1: HPLC chromatogram of crude **13**. Jupiter C18, 300 Å, 250 × 4.6 mm column packing; detection: 260 nm; flow rate: 1.0 mL min⁻¹; eluents: A: 0.1% TFA in water : acetonitrile = 99:1., B: 0.1% TFA in water:acetonitrile=50:50; gradient: 0–50% (v/v) B in A during 50 min.




Figure S2: HPLC chromatogram of the purified **13**. Jupiter C18, 300 Å, 250 × 4.6 mm column packing; detection: 260 nm; flow rate: 1.0 mL min⁻¹; eluents: A: 0.1% TFA in water : acetonitrile = 99:1., B: 0.1% TFA in water:acetonitrile=50:50; gradient: 0–50% (v/v) B in A during 50 min.





Figure S3: ESI mass spectrum of the purified compound 13.

¹H and ¹³C NMR spectra of the compounds

